Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Gains from Sales and Divestitures (2022 - 2025)

Definitive Healthcare (DH) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $62821.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 86.86% year-over-year to $62821.0, compared with a TTM value of $62821.0 through Dec 2025, down 86.86%, and an annual FY2025 reading of $62821.0, down 86.86% over the prior year.
  • Gains from Sales and Divestitures was $62821.0 for Q4 2025 at Definitive Healthcare, down from $478010.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $716776.0 in Q4 2022 and bottomed at $62821.0 in Q4 2025.
  • Average Gains from Sales and Divestitures over 3 years is $352117.2, with a median of $314436.0 recorded in 2022.
  • Peak annual rise in Gains from Sales and Divestitures hit 86.86% in 2025, while the deepest fall reached 86.86% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $716776.0 in 2022, then crashed by 33.31% to $478010.0 in 2024, then plummeted by 86.86% to $62821.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for DH at $62821.0 in Q4 2025, $478010.0 in Q4 2024, and $716776.0 in Q4 2022.